7-116775073-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The ENST00000397752.8(MET):c.3221G>A(p.Ser1074Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000254 in 1,614,040 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S1074G) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000397752.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MET | NM_000245.4 | c.3221G>A | p.Ser1074Asn | missense_variant | 15/21 | ENST00000397752.8 | NP_000236.2 | |
MET | NM_001127500.3 | c.3275G>A | p.Ser1092Asn | missense_variant | 15/21 | NP_001120972.1 | ||
MET | NM_001324402.2 | c.1931G>A | p.Ser644Asn | missense_variant | 14/20 | NP_001311331.1 | ||
MET | XM_011516223.2 | c.3278G>A | p.Ser1093Asn | missense_variant | 16/22 | XP_011514525.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MET | ENST00000397752.8 | c.3221G>A | p.Ser1074Asn | missense_variant | 15/21 | 1 | NM_000245.4 | ENSP00000380860 | P3 | |
MET | ENST00000318493.11 | c.3275G>A | p.Ser1092Asn | missense_variant | 15/21 | 1 | ENSP00000317272 | A2 | ||
MET | ENST00000436117.3 | c.*826G>A | 3_prime_UTR_variant, NMD_transcript_variant | 14/20 | 1 | ENSP00000410980 | ||||
MET | ENST00000454623.1 | downstream_gene_variant | 5 | ENSP00000398140 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152194Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.0000321 AC: 8AN: 249488Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 135346
GnomAD4 exome AF: 0.0000253 AC: 37AN: 1461846Hom.: 0 Cov.: 31 AF XY: 0.0000289 AC XY: 21AN XY: 727230
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152194Hom.: 1 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74356
ClinVar
Submissions by phenotype
Autosomal recessive nonsyndromic hearing loss 97 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 06, 2024 | - - |
Renal cell carcinoma Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1092 of the MET protein (p.Ser1092Asn). This variant is present in population databases (rs752641437, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with MET-related conditions. ClinVar contains an entry for this variant (Variation ID: 246637). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MET protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Papillary renal cell carcinoma type 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Jul 07, 2022 | The MET c.3275G>A (p.Ser1092Asn) missense change has a maximum subpopulation frequency of 0.0071% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with hereditary papillary renal cell carcinoma. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
Hereditary cancer-predisposing syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 28, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at